[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
웹진발간
스폰서배너광고 안내  배너1
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
김서영
김서영 (Seoyoung C Kim) 저자 이메일 보기
Brigham and Women's Hospital
 
조회 488  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study
열기 Authors and Affiliations

Abstract

Objective To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors (TNFi) or abatacept.

Methods Using claims data from US Medicare from 2010 to 2015, and IMS and MarketScan from 2011 to 2015, we identified adults with RA who initiated TCZ or TNFi (primary comparator)/abatacept (secondary comparator) with prior use of ≥1 different biologic drug or tofacitinib. The primary outcome was hospitalised serious infection (SI), including bacterial, viral or opportunistic infection. To control for >70 confounders, TCZ initiators were propensity score (PS)-matched to TNFi or abatacept initiators. Database-specific HRs were combined by a meta-analysis.

Results The primary cohort included 16 074 TCZ PS-matched to 33 109 TNFi initiators. The risk of composite SI was not different between TCZ and TNFi initiators (combined HR 1.05, 95%?CI 0.95 to 1.16). However, TCZ was associated with an increased risk of serious bacterial infection (HR 1.19, 95%?CI 1.07 to 1.33), skin and soft tissue infections (HR 2.38, 95%?CI 1.47 to 3.86), and diverticulitis (HR 2.34, 95%?CI 1.64 to 3.34) versus TNFi. An increased risk of composite SI, serious bacterial infection, diverticulitis, pneumonia/upper respiratory tract infection and septicaemia/bacteraemia was observed in TCZ versus abatacept users.

Conclusions This large multidatabase cohort study found no difference in composite SI risk in patients with RA initiating TCZ versus TNFi after failing ≥1 biologic drug or tofacitinib. However, the risk of serious bacterial infection, skin and soft tissue infections, and diverticulitis was higher in TCZ versus TNFi initiators. The risk of composite SI was higher in TCZ initiators versus abatacept.

논문정보
- 형식: Research article
- 게재일: 2019년 01월 (BRIC 등록일 2019-01-31)
- 연구진: 국외연구진
- 분야: Medicine
RNF20/40 의존적 eEF1BδL 모노유비퀴틴화에 의한 열충격 유전자 전사 조절[Nucleic Acids Res.]
인선아
발표: 인선아 (KAIST)
일자: 2019년 2월 22일 (금) 오후 02시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
등록
 
목록
BRIC 배너광고
관련링크
김서영 님 전체논문보기 >
관련분야 논문보기
Medicine

외부링크
Google (by Seoyoung C Kim)
Pubmed (by Seoyoung C Kim)
프리미엄 Bio일정 Bio일정 프리미엄 안내
2019 Korean Researchers’ Night in AACR 참가 신청 안내 (미국 애틀랜타)
2019 Korean Researchers’ Night in AACR 참가 신청 안내 (미국 애틀랜타)
사전접수: ~2019.02.20
날짜: 2019.03.31
장소: Atlanta Marriott Marquis
[BRIC Webinar]RNF20/40 의존적 eEF1BδL 모노유비퀴틴화에 의한 열충격 유전자 전사 조절-인선아 (KAIST)
2019 서경배과학재단 신진과학자 연구지원 프로그램 공고
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북    RSS서비스 RSS
1550398093 0.17931500
1550398093 0.60685600
0.42754101753235 초 소요